A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice

Kiersten Giusto, Manali Patki, Jagadish Koya, Charles R. Ashby, Swapna Munnangi, Ketan Patel, Sandra E. Reznik

Research output: Contribution to journalArticle

1 Scopus citations


Aim: Previously, we have shown that inhibition of SphK by the SphK inhibitor-II (SKI II) prevents lipopolysaccharide-induced preterm birth in mice. The aim of this study was to develop a vaginal self-nanoemulsifying drug-delivery system (SNEDDS) for SKI II. Materials & methods: A SKI II-loaded SNEDDS was characterized and tested in a murine preterm birth model. Results: The SNEDDS immediately formed a gel and then slowly emulsified to nanoglobules with over 500-fold enhancement of SKI II solubility at vaginal pH. Intravaginal administration of the SKI II SNEDDS significantly decreased lipopolysaccharide-induced preterm birth in mice. Conclusion: A vaginal nanoformulation of SKI II represents a novel, noninvasive approach to prevent preterm birth.

Original languageEnglish (US)
Pages (from-to)2835-2851
Number of pages17
Issue number21
StatePublished - Jan 1 2019



  • inflammation
  • lipopolysaccharide
  • nanoformulation
  • preterm birth
  • SKI II
  • sphingosine kinase inhibitor
  • vaginal administration

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Cite this